• SEC Form 10-K for year ending June 30, 2002. Contains sales and royatly figures for the company's largest selling products, firm-level R&D figures, information on lawsuits filed against the firm, income and cost data, stock information, and financial holdings.
• Notice of 2001 Annual Meeting and Proxy Statement. Contains exececutive compensation figures, including salaries and stock options.

Myriad has received patents for two genes, BRCA-1 and BRCA-2, used to perform a cancer screening tests. According to the firm's SEC Form 10-K, "BRCA-1 and BRCA-2 appear to be responsible for approximately 84% of the early onset hereditary breast cancer and approximately 90% of hereditary ovarian cancer." Myriad has licensed the rights to perform these tests to about a dozen laboratories in exchange for very high royalties on each test performed. (The federal government brokered a deal to pay lower royalties when the genes are used by NCI and NIH-sponsored research institutions and investigators.) Myriad is currently trying to enforce patents on the BRCA-1 and BRCA-2 genes in Europe and Canada, which is has led to a lot of controversy in their public health communities because this would raise the price of testing for cancer considerably.

In January 2005, the European Patent Office rejected the essential points of BRCA1 gene patents.

• January 31, 2005. Curie Institute. Another victory for opponents of patents held by Myriad Genetics: European Patent Office rejects the essential points of BRCA1 gene patents.

• Patents

  • BRCA-1:
    • 5,693,473: Linked breast and ovarian cancer susceptibility gene.
    • 5,709,999: Linked breast and ovarian cancer susceptibility gene.
    • 5,710,001: 17q-linked breast and ovarian cancer susceptibility gene.
    • 5,753,441: 170-linked breast and ovarian cancer susceptibility gene.
    • 6,030,832: Carboxy-terminal BRCA1 interacting protein.
    • 6,162,897: 17q-linked breast and ovarian cancer susceptibility gene.
  • BRCA-2:
    • 6,033,857: Chromosome 13-linked breast cancer susceptibility gene.,
    • 5,837,492: Chromosome 13-linked breast cancer susceptibility gene.

• Myriad Press Releases

  • May 24, 2002. Myriad Genetics' BRAC Analysis Test Supported by Two New Studies; BRACAnalysis Essential in Saving Lives From Breast and Ovarian Cancer.
  • May 19, 2001. Myraid Genetics Awarded Three U.S. Patents and Eight International Patents.
  • February 15, 2001. Myriad Genetics And Kaiser Permanente Sign Agreement For Breast Cancer Testing.
  • November 17, 1998. Myriad Genetics Awarded Broad U.S. Patent on BRCA-2 Gene.
  • May 18, 1998. Myriad Genetics Obtains OncorMed's BRCA1/BRCA2 Genetic Testing Program in Patent Settlement.

• Misc. Sources

  NIH Documents

  • NIH Questions and Answers on BRCA-1 and BRCA-2
  • January 6, 2003. Ontario Ministry of Health and Long-Term Care press release. Eves government and Ontario Women's Health Council invest $1.2 million in new genetic test for cancer.
  • July 31, 1997, NIH News Advisory, NIEHS Shortcut Isolates and Clones BRCA2 Gene in Yeast; Success Leads to Establishment of Gene Isolation Unit
  • March 5, 1997, NIH News Advisory, NIEHS Researcher Breaks New Ground in the Fight Against Breast Cancer
  • October 4, 2001. European Union. Resolution on the Patenting of BRCA1 and BRCA2 ('Breast Cancer') Genes.
  • September 19, 2001. Speech by Tony Clement, Canadian Minister of Health and Long-Term Care. The Myriad Gene Patent Issue.
  • April 20, 2001. York University press release. PhD study of genetic testing for breast cancer in the US and UK illustrates private vs public approach to genetic medicine.

• News Stories:

  • February 27, 2003. Ken Ernhofer for the Christian Science Monitor. Ownership of genes at stake in potential lawsuit.
  • January 10, 2003. The Edmonton Journal. Gene-patent policy review urgently needed.
  • January 8, 2003. Norma Greenaway for the Ottowa Citizen. UBC geneticist urges battle against gene patenting: Patricia Baird says genetic screening will be unaffordable for most if patenting is allowed.
  • January 7, 2003. Carolyn Abraham for the Toronto Globe. Ontario to fight for gene test Clement challenges U.S. firm's monopoly on screening for breast, ovarian cancer.
  • January 7, 2003. April Lindgren for the Kingston Whig-Standard. Kingston General Hospital to use disputed gene test for cancer.
  • January 7, 2003. Karen Palmer for the Toronto Star. Battle over cancer gene test.
  • January 7, 2003. The Ottowa Citizen. Ontario Defies Firm's Gene Patent.
  • November 9, 2002. Syndey Morning Herald. Cancer Capitalists.
  • September 26, 2002. Gautan Naik for the Wall Street Journal. Myriad Faces Challenges To Its Cancer-Gene Patents.
  • September 23, 2001. Canada News Wire. Increased federal funding and gene patenting Ontario priorities at health ministers' meeting.
  • September 21, 2001. Dennis Bueckert for the Canadian Press. Federal officials dismiss Ontario's concerns about gene patenting.
  • September 19, 2001. Canadian Press. Ontario defies U.S. gene company over cancer test, arguing health care at risk.
  • February 24, 2002. Kimberly Blanton fpr the Boston Globe. Corporate Takeover.
  • December 11, 2001. Sarah Sexton for Health Matters. No Patent, No Cure?
  • December, 2001. Seth Shulman for Technology Review. Owning the Future: Doctors wihtout Patents.
  • October 26, 2001. PatNews. Europeans fighting Myriad Genetics BRCA1 breast cancer gene.
  • October 1, 2001. Meredith Wadman for Fortune. Europe's Patent Rebellion.
  • September 21, 2001. Wendy McLellan fro The Vancouver Province. Cost rules out cancer test for women in British Columbia.
  • September 21, 2001. Canadian Press. Federal officials dismiss Ontario's concerns about gene patenting.
  • September 19, 2001. Canadian Press. Ontario defies U.S. gene company over cancer test, arguing health care at risk.
  • September 8, 2001. Jon Henley for the Guardian. Cancer Unit Fights US Gene Patent.
  • September 5, 2001. The Canadian Press. B.C. women left hanging by patent war over breast cancer test.
  • August 3, 2001. Paul Willcocks for Reuters. Canadian premiers wade into gene patenting debate.
  • April 26, 2001, Rachel Sylvester for The Telegraph. NHS deal on gene test for cancer.
  • March 21, 2000. Canadian Broadcasting Corporation. This Morning with Michael Enright. The Impact Of Gene Patents on Health Care and Medical Research: The case of Breast Cancer Genetice Screening.
  • February 21, 2000. Vida Foubister for the American Medical News, Firm's patents on breast cancer genes illustrate concerns.
  • February 8, 2000. Los Angeles Times, Aggressive Patenting May Stifle Gene Discovery Benefits
  • January 19, 2000. The Salt Lake Tribune, British Balk at Utah Company's Attempt to Patent Gene in Europe
  • January 17, 2001. James Meek for the Guardian. US firm may double cost of UK cancer checks.
  • February 21, 2000. American Medical News. Firm's patents on breast cancer genes illustrate concerns.
  • June 17, 1996. Chris O-Brian for the News and Observer. Groups debate wisdom of patenting gene.
  • December 15, 1999, Julian Borger, in The Guardian, Rush to patent genes stalls cures for disease
  • October 18, 1999, Vida Foubister, in American Medical News, Lapses in practice, oversight undercut genetic testing
  • October 11, 1999, Steve Bunk, in the New Scientist, Researchers Feel Threatened by Disease Gene Patents

• October 14, 2000. PR Newswire. Myriad Genetics awarded US patent on p16 cancer protein.
• July 18, 2000. Patent #6,090,578: MTS1 Gene.

• October 9, 2000, Pharm-Policy archives, Myriad's Academic Collaborations
• October 4, 2000, Myriad Press Release, Myriad Genetics Presents Prostate Cancer Gene At Annual Ashg Meeting Apparently Myriad will also have rights to the HPC2 prostate cancer gene.
• September 28, 2000, Myriad Press Release, Myriad Genetics Launches COLARIS? Colon Cancer Test The price for Mryiad's test on the MLH1 and MSH2 genes is $1,950.
• August 30, 1998, Kristen Moulton, in the Associated Press, Those Utah genes - Mormon's affinity for big families and genealogy are geneticist's dream come true

Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City, UT 84108
801-584-3600